Norwegian Prostate Cancer Registry

The Norwegian Prostate Cancer Registry contains data on prostate cancer dating back to 2004.
Last updated: 8/31/2022

This annual report includes patients with prostate cancer for the period 2004–2021. The reference group for the Norwegian Prostate Cancer Registry has defined quality indicators relevant for this group of patients accompanied by target levels of achievement. See table 1.1 for an overview of results and national quality indicators.

The quality indicators established in 2018 have been kept in the 2021 report. Overall, the quality of prostate cancer treatment and diagnostics is good, and it seems that Norwegian men gets equal care across the country. A report like this will always be affected by natural variation in the patient population, and may not indicate differences in practice. However we hope the departments will evaluate their own results more in depth, to see if their own practice should be improved or changed.

Prostate cancer treatment may be associated with late effects, especially related to urinary incontinence, sexual- and intestinal function. One can see effects after surgery and radiation treatment, all with the exception of that intestinal function do not seem to be affected by surgery. There is some variation between the hospitals, but it cannot be established that there are any hospitals that have results that deviate significantly from the national average.

80 % of the patients stated that they to a very large or large extent received sufficent information about which treatment options that were relevant, while 64 % thought they had received sufficient informastion about possible side effects and late effects. When questioned about satisfaction with the treatment the patients were offered at the hospital, 88 % stated that they to a very large or large extent were satisfied.